Literature DB >> 21335190

Recommendations for use of marginal donors in heart transplantation: Brazilian Association of Organs Transplantation guideline.

A I Fiorelli1, N A G Stolf, P M Pego-Fernandes, J L Oliveira Junior, R H B Santos, C A M Contreras, D D L Filho, J J Dinkhuysen, M C V Moreira, J A C Mejia, M C R Castro.   

Abstract

The high prevalence of heart failure has increased the candidate list for heart transplantation; however, there is a shortage of viable donated organs, which is responsible for the high mortality of patients awaiting a transplantation. Because the marginal donor presents additional risk factors, it is not considered to be an ideal donor. The use of a marginal donor is only justified in situations when the risk of patient death due to heart disease is greater than that offered by the donor. These recommendations sought to expand the supply of donors, consequently increasing the transplant rate. We selected articles based on robust evidence to provide a substratum to develop recommendations for donors who exceed the traditional acceptance criteria. Recipient survival in the immediate postoperative period is intimately linked to allograft quality. Primary allograft failure is responsible for 38% to 40% of immediate deaths after heart transplantation: therefore; marginal donor selection must be more rigorous to not increase the surgical risk. The main donor risk factors with the respective evidence levels are: cancer in the donor (B), female donor (B), donor death due to hemorrhagic stroke (B), donor age above 50 years (relative risk [RR] = 1.5) (B), weight mismatch between donor and recipient < 0.8 (RR = 1.3) (B), ischemia > 240 minutes (RR = 1.2) (B), left ventricular dysfunction with ejection fraction below 45% (B), and use of high doses of vasoactive drugs (dopamine > 15 mg/kg·min) (B). Factors that impact recipient mortality are: age over 50 years (RR = 1.5); allograft harvest at a distance; adult recipient weighing more than 20% of the donor; high doses of vasoactive drugs (dopamine greater than 15 mg/kg·min) and ischemic time >4 hours. The use of a marginal donor is only justified when it is able to increase life expectancy compared with clinical treatment, albeit the outcomes are interior to those using an ideal donor.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21335190     DOI: 10.1016/j.transproceed.2010.12.047

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  4 in total

1.  Guidelines for the assessment and acceptance of potential brain-dead organ donors.

Authors:  Glauco Adrieno Westphal; Valter Duro Garcia; Rafael Lisboa de Souza; Cristiano Augusto Franke; Kalinca Daberkow Vieira; Viviane Renata Zaclikevis Birckholz; Miriam Cristine Machado; Eliana Régia Barbosa de Almeida; Fernando Osni Machado; Luiz Antônio da Costa Sardinha; Raquel Wanzuita; Carlos Eduardo Soares Silvado; Gerson Costa; Vera Braatz; Milton Caldeira Filho; Rodrigo Furtado; Luana Alves Tannous; André Gustavo Neves de Albuquerque; Edson Abdala
Journal:  Rev Bras Ter Intensiva       Date:  2016-09

2.  Institutional volume of heart transplantation with left ventricular assist device explantation influences graft survival.

Authors:  Nicholas A Haglund; Irene D Feurer; Rashid M Ahmad; Thomas G DiSalvo; Daniel J Lenihan; Mary E Keebler; Kelly H Schlendorf; John M Stulak; Mark A Wigger; Simon Maltais
Journal:  J Heart Lung Transplant       Date:  2014-05-15       Impact factor: 10.247

3.  The Impact of Donor and Recipient Renal Dysfunction on Cardiac Allograft Survival: Insights Into Reno-Cardiac Interactions.

Authors:  Olga Laur; Meredith A Brisco; Alexander J Kula; Susan J Cheng; Abeel A Mangi; Lavanya Bellumkonda; Daniel L Jacoby; Steven Coca; W H Wilson Tang; Chirag R Parikh; Jeffrey M Testani
Journal:  J Card Fail       Date:  2015-11-23       Impact factor: 5.712

4.  Comparison of early versus delayed timing of left ventricular assist device implantation as a bridge-to-transplantation: An analysis of the UNOS dataset.

Authors:  Shuichi Kitada; P Christian Schulze; Zhezhen Jin; Kevin Clerkin; Shunichi Homma; Donna M Mancini
Journal:  Int J Cardiol       Date:  2015-11-09       Impact factor: 4.164

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.